AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Dosing FAQs
Broadcast Date
Therapeutic Area
Cardiovascular
Dr. Michael Heffernan addresses frequently asked questions about the dosing regimens of PCSK9 inhibitors - monoclonal antibodies (mAbs) and small interfering RNA (siRNA).
